CargoAdmin, Bureaucrats, Moderators (CommentStreams), fileuploaders, Interface administrators, newuser, Push subscription managers, Suppressors, Administrators
14,662
edits
Cencora: Difference between revisions
m
Text replacement - "The New York Times" to "The New York Times"
(from https://en.wikipedia.org/wiki/Cencora) |
m (Text replacement - "The New York Times" to "The New York Times") |
||
| Line 54: | Line 54: | ||
*On June 2, 2021, AmerisourceBergen acquired Alliance Healthcare from [[Walgreens Boots Alliance]] for approximately $6.5 billion, made up of $6.275 billion in cash and 2 million shares of AmerisourceBergen common stock.<ref>{{Cite press release|title=Walgreens Boots Alliance Completes Strategic Transaction with AmerisourceBergen Divesting Alliance Healthcare Businesses|url=https://www.businesswire.com/news/home/20210602005360/en/Walgreens-Boots-Alliance-Completes-Strategic-Transaction-with-AmerisourceBergen-Divesting-Alliance-Healthcare-Businesses|website=Businesswire|language=en}}</ref> | *On June 2, 2021, AmerisourceBergen acquired Alliance Healthcare from [[Walgreens Boots Alliance]] for approximately $6.5 billion, made up of $6.275 billion in cash and 2 million shares of AmerisourceBergen common stock.<ref>{{Cite press release|title=Walgreens Boots Alliance Completes Strategic Transaction with AmerisourceBergen Divesting Alliance Healthcare Businesses|url=https://www.businesswire.com/news/home/20210602005360/en/Walgreens-Boots-Alliance-Completes-Strategic-Transaction-with-AmerisourceBergen-Divesting-Alliance-Healthcare-Businesses|website=Businesswire|language=en}}</ref> | ||
In June 2020, the [[United States Department of Health and Human Services|U.S. Department of Health and Human Services (HHS)]] announced an unusual agreement for the distribution of [[remdesivir]], the first coronavirus drug. HHS agreed to manufacturer [[Gilead Sciences |Gilead]]'s [[Wholesale acquisition cost|wholesale acquisition price]], while HHS would continue to work together with state governments and AmerisourceBergen to allocate shipments of remdesivir vials to American hospitals through the end of September 2020, and in exchange, during that time-frame American patients would be allocated over 90% of Gilead's projected remdesivir output of more than 500,000 treatment courses.<ref name="Kolata">{{cite news |last1=Kolata |first1=Gina | name-list-style = vanc |title=Remdesivir, the First Coronavirus Drug, Gets a Price Tag |url=https://www.nytimes.com/2020/06/29/health/coronavirus-remdesivir-gilead.html |work= | In June 2020, the [[United States Department of Health and Human Services|U.S. Department of Health and Human Services (HHS)]] announced an unusual agreement for the distribution of [[remdesivir]], the first coronavirus drug. HHS agreed to manufacturer [[Gilead Sciences |Gilead]]'s [[Wholesale acquisition cost|wholesale acquisition price]], while HHS would continue to work together with state governments and AmerisourceBergen to allocate shipments of remdesivir vials to American hospitals through the end of September 2020, and in exchange, during that time-frame American patients would be allocated over 90% of Gilead's projected remdesivir output of more than 500,000 treatment courses.<ref name="Kolata">{{cite news |last1=Kolata |first1=Gina | name-list-style = vanc |title=Remdesivir, the First Coronavirus Drug, Gets a Price Tag |url=https://www.nytimes.com/2020/06/29/health/coronavirus-remdesivir-gilead.html |work=The New York Times |date=29 June 2020 |access-date=29 June 2020}}</ref><ref name="HHSPressRelease_29June2020">{{cite press release |title=Trump Administration Secures New Supplies of Remdesivir for the United States |url=https://www.hhs.gov/about/news/2020/06/29/trump-administration-secures-new-supplies-remdesivir-united-states.html |publisher=[[U.S. Department of Health and Human Services]] (HHS) |date=29 June 2020 |access-date=29 June 2020 |archive-date=June 29, 2020 |archive-url=https://web.archive.org/web/20200629144040/https://www.hhs.gov/about/news/2020/06/29/trump-administration-secures-new-supplies-remdesivir-united-states.html |url-status=dead }}</ref> | ||
==Finances== | ==Finances== | ||
For the fiscal year 2019, AmerisourceBergen reported earnings of US$1.11 billion, with an annual revenue of US$179.58 billion. AmerisourceBergen's shares traded at over $88 per share, and its market capitalization was valued at over US$19.2 billion in September 2019.<ref>{{Cite web|url=http://investor.amerisourcebergen.com/financial-information/annual-reports|title=Financial Reports {{!}} AmerisourceBergen Corporation|website=AmerisourceBergen Corporation|language=en|access-date=2018-11-07}}</ref> | For the fiscal year 2019, AmerisourceBergen reported earnings of US$1.11 billion, with an annual revenue of US$179.58 billion. AmerisourceBergen's shares traded at over $88 per share, and its market capitalization was valued at over US$19.2 billion in September 2019.<ref>{{Cite web|url=http://investor.amerisourcebergen.com/financial-information/annual-reports|title=Financial Reports {{!}} AmerisourceBergen Corporation|website=AmerisourceBergen Corporation|language=en|access-date=2018-11-07}}</ref> | ||